hotspot -WSS

hotspot

author：Wikipedia 2025-09-30 16:27:19 - browse：5

Telehealth menopause treatment options displayed on cellphones emerging from a crack in the ground. -- health tech coverage from STAT — Molly Ferguson for STAT

At the turn of the century, nearly 18 million women in the United States were battling hot flashes, night sweats, and other symptoms of menopause with hormones. But in 2002, the therapy went into a free-fall when a landmark trial suggested treating menopause with estrogen and progesterone increased the risk of breast cancer and cardiovascular disease. The study was shut down early — and a year later, prescriptions had plummeted to nearly half what they had been in 2001.

More than two decades later, menopause experts have come to think about the results of the trial very differently. Newer research points to more benefits than risks for many healthy women under 60 treating menopause symptoms with hormone therapy. But many women who are good fits still aren’t getting treatment. “The pendulum has been slowly — too slowly — swinging back,” said OB-GYN Mike Green, chief medical officer of menopause telehealth company Winona.

Winona is part of a new generation of virtual-first health care companies aiming to give that pendulum a push. In the last five years, more than a dozen telehealth companies have started up to serve women in and approaching menopause, including with hormone therapy.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： Mitch McConnell episode has important public health takeaway

explore

WSS

PEPFAR is under serious threat — and so is global health

FDA approves updated Covid vaccines

Long Covid needs a new name — and a new frame

What the US credit downgrade means for the economy, your finances

Popular nasal decongestant doesn't actually relieve congestion

IRA could hurt research into orphan drugs for rare diseases

leisure time

hotspot

focus

Medicare details structure of new drug price negotiation program

Generate Biomedicines machine learning biotech raises $273M

Medicare details structure of new drug price negotiation program

‘Oppenheimer’ and the risks of AI in health care

Sports medicine is finally prioritizing gender equality

IRA could hurt research into orphan drugs for rare diseases

Drug repurposing or repositioning? The language matters

Acelyrin, a rare IPO success, stumbles in its first big test

Medical records are filled with copy

New weight loss drugs vying to be the next Wegovy or Mounjaro

Wikipedia

IRA could hurt research into orphan drugs for rare diseases

How to make the FDA’s new prescription one

How housing is health care on Long Island

FDA proposes changes to key medical devices approval pathway

Tire on Delta flight pops while landing in Atlanta, 1 person injured, airline says

Amazon expands telehealth clinic nationwide

focus

explore

focus

explore